Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiac Biotech SolutionsCBSC EV-to-EBITDA is -12.18 as of Jul. 14, 2026. Among 511 Medical Devices & Instruments companies, Cardiac Biotech Solutions ranks worse than 195694.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cardiac Biotech Solutions's enterprise value is $5.30 Mil.
Cardiac Biotech Solutions's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.44 Mil. Therefore, Cardiac Biotech Solutions's EV-to-EBITDA for today is -12.18.
The historical rank and industry rank for Cardiac Biotech Solutions's EV-to-EBITDA or its related term are showing as below:
CBSC's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 14.2 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiac Biotech Solutions's PE Ratio (TTM) for today is calculated as:
Cardiac Biotech Solutions's share price for today is $0.03.
Cardiac Biotech Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBSC vs LUCY, NXGL, MHUAF: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiac Biotech Solutions EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cardiac Biotech Solutions's EV-to-EBITDA falls into.
Cardiac Biotech Solutions's current Enterprise Value is $5.30 Mil.
Cardiac Biotech Solutions's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiac Biotech Solutions (CBSC) has a EV-to-EBITDA of -12.18 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiac Biotech Solutions. According to the industry distribution chart, Cardiac Biotech Solutions ranks #999999 out of 511 companies in the Medical Devices & Instruments industry.
Is Cardiac Biotech Solutions' EV-to-EBITDA too high?
Cardiac Biotech Solutions' current EV-to-EBITDA is -12.18. Based on the distribution chart, Cardiac Biotech Solutions ranks #999999 out of 511 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Cardiac Biotech Solutions' EV-to-EBITDA compare to LUCY and NXGL?
According to the Medical Devices & Instruments industry distribution chart, Cardiac Biotech Solutions ranks #999999 out of 511 companies for EV-to-EBITDA. This places Cardiac Biotech Solutions in the lower half of its industry. The industry median EV-to-EBITDA is 14.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cardiac Biotech Solutions. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiac Biotech Solutions's current EV-to-EBITDA is -12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current EV-to-EBITDA of -12.18. The current EV-to-EBITDA is -12.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current EV-to-EBITDA is -12.18 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBSC has been successfully added to your 
